Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion

Abstract

Background: The aim of this study was to evaluate and compare the clinical and angiographic outcomes of 3 drug-eluting stents (DES) in patients with large vessel diameter and single coronary artery lesions. Hypothesis: The efficacy of 3 DESs may be similar. Methods: A total of 411 consecutive patients who visited 3 university hospitals from June 2004 to December 2007 and had a single coronary lesion which was treated with the use of a DES that was 3.5 mm in diameter were enrolled in this study. Patients were divided into 3 stent groups: Paclitaxel-eluting stent (PES, n=105), Sirolimus-eluting stent (SES, n=259), and Zotarolimus-eluting stent (ZES, n=47). The study end point was a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), and ischemia-driven target-vessel revascularization (TVR) for 12 months. Results: Baseline characteristics were not different. Late loss was higher in the ZES group than the other stents (0.5 ± 0.4 mm in SES vs 0.3 ± 0.5 mm in PES, 0.7 ± 0.5 mm in ZES, P = 0.001). The total MACE-free survival rate was not significantly different between the SES group and the PES group (98.8% in SES vs 97.1% in PES, P = 0.252) or the PES group and the ZES group (97.1% in PES vs 93.6% in ZES, P = 0.301). However, the SES group showed a significantly better MACE-free survival rate compared with the ZES group (98.8% in SES vs 93.6% in ZES, P = 0.018). Conclusions: Clinical and angiographic outcomes of DES in a large vessel diameter and single coronary artery is excellent and SES appears to show better angiographic and clinical outcomes than ZES. © 2010 Wiley Periodicals, Inc.